Patents by Inventor Masafumi Matsuo

Masafumi Matsuo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20070082861
    Abstract: Oligonucleotides having a nucleotide sequence complementary to nucleotide numbers such as 2571-2607, 2578-2592, 2571-2592, 2573-2592, 2578-2596, 2578-2601 or 2575-2592 of the dystrophin cDNA (Gene Bank accession No. NM_004006.1) and therapeutic agents for muscular dystrophy comprising such oligonucleotides.
    Type: Application
    Filed: November 21, 2003
    Publication date: April 12, 2007
    Applicants: Masafumi Matsuo, Yasuhiro Takeshima, Nonpro. Org. Trans. Res. Org. of Duch. Musc. Dys.
    Inventors: Masafumi Matsuo, Yasuhiro Takeshima, Makoto Koizumi
  • Patent number: 6727355
    Abstract: The invention provides an isolated and purified DNA set forth as SEQ ID NO:15 in the Sequence Listing and an antisense oligonucleotide complementary to the DNA. The DNA represents the splicing enhancer sequence (SES) in exon 45 of human dystrophin gene, and serves as a template in preparation of the antisense oligonucleotide, which is used to induce exon 45 skipping in certain group of patient with Duchenne muscular dystrophy to restore the reading frame of dystrophin mRNA.
    Type: Grant
    Filed: August 16, 2001
    Date of Patent: April 27, 2004
    Assignees: JCR Pharmaceuticals Co., Ltd.
    Inventors: Masafumi Matsuo, Shoichiro Kamei
  • Patent number: 6653467
    Abstract: Antisense oligonucleotides comprising a nucleotide sequence complementary to the nucleotide sequence of SEQ ID NO:1 or NO:2 are disclosed. The antisense oligonucleotides are used for treatment of specific types of Duchenne muscular dystrophy which is attributed to a change in number of the nucleotides composing one or more exons adjacent to exon 43 or 53, respectively, in human dystrophin mRNA, wherein the change is due to deletion of one or more nucleotides from the normal nucleotide sequence for the exons, wherein the net of the change in number of the nucleotides is expressed as a reduction of (3×N+1) nucleotides, wherein N is zero or a natural number.
    Type: Grant
    Filed: September 22, 2000
    Date of Patent: November 25, 2003
    Assignees: JCR Pharmaceutical Co., Ltd.
    Inventors: Masafumi Matsuo, Yasuhiro Takeshima
  • Patent number: 6653466
    Abstract: A therapeutic pharmaceutical composition for patients of Duchenne muscular dystrophy with entire loss of exon 20 in dystrophin mature mRNA is provided. The composition comprise as an active principle an antisense oligonucleotide consisting of a 20 to 50-nucleotide sequence against exon 19 of the dystrophin pre-mRNA.
    Type: Grant
    Filed: July 31, 2001
    Date of Patent: November 25, 2003
    Assignees: JCR Pharmaceuticals Co., Ltd.
    Inventor: Masafumi Matsuo
  • Patent number: 6548284
    Abstract: Disclosed are metalloprotease proteins or their salts usable for treatment or prophylaxis of conformational diseases and for providing a screening kit for selection of carcinostatics and anti-metastatic agents. The metalloprotease proteins have an amino acid sequence set forth under SEQ ID NO:1 or NO:2 in the Sequence Listing. The proteins have a neutral optimal pH, hydrolyze endothelin 1, atrial natriuretic peptide and angiotensin I and are inhibited by 1,10-phenanthroline, phosphoramidon and thiorphan.
    Type: Grant
    Filed: November 3, 2000
    Date of Patent: April 15, 2003
    Assignees: JCR Pharmaceuticals Co., Ltd.
    Inventors: Masafumi Matsuo, Koji Ikeda, Noriaki Emoto, Sunu Budhi Raharjo, Yudha Nurhantari, Kayoko Saiki, Mitsuhiro Yokoyama
  • Publication number: 20020055481
    Abstract: The invention provides an isolated and purified DNA set forth as SEQ ID NO:15 in the Sequence Listing and an antisense oligonucleotide complementary to the DNA. The DNA represents the splicing enhancer sequence (SES) in exon 45 of human dystrophin gene, and serves as a template in preparation of the antisense oligonucleotide, which is used to induce exon 45 skipping in certain group of patient with Duchenne muscular dystrophy to restore the reading frame of dystrophin mRNA.
    Type: Application
    Filed: August 16, 2001
    Publication date: May 9, 2002
    Applicant: JCR PHARMACEUTICALS CO., Ltd.
    Inventors: Masafumi Matsuo, Shoichiro Kamei
  • Publication number: 20010056077
    Abstract: A therapeutic pharmaceutical composition for patients of Duchenne muscular dystrophy with entire loss of exon 20 in dystrophin mature mRNA is provided. The composition comprise as an active principle an antisense oligonucleotide consisting of a 20 to 50-nucleotide sequence against exon 19 of the dystrophin pre-mRNA.
    Type: Application
    Filed: July 31, 2001
    Publication date: December 27, 2001
    Applicant: JCR PHARMACEUTICALS CO., LTD
    Inventor: Masafumi Matsuo